2026-01-02 - Analysis Report
Here's a breakdown of the provided data for TransMedics Group Inc (TMDX), followed by a comprehensive analysis:

**1. Return Rate Comparison (vs. S&P 500)**

*   **Ticker:** TMDX
*   **Company:** TransMedics Group Inc
*   **Overview:** TransMedics is a medical technology company focused on preserving and assessing organs for transplant.
*   **TMDX Cumulative Return:** 199.35%
*   **VOO (S&P 500) Cumulative Return:** 76.55%
*   **Divergence:** 122.8 (Relative Divergence: 61.3)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period for which the cumulative return is measured. The divergence of 122.8 suggests that TMDX's returns have far exceeded those of the broader market index. The relative divergence of 61.3 indicates that the current divergence is in the middle of the historical range.

**Alpha, Beta Analysis:**

|            Year |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|-----------------:|-------:|------:|--------:|-------:|---------:|
| 2020-2022        |  252   |  83.5 |   234   |    1.3 |      2.1 |
| 2021-2023        |  246   |  80.5 |   218   |    1.7 |      2.7 |
| 2022-2024        |  293   |  85.5 |   263   |    1.8 |      2.1 |
| 2023-2025        |   93   |  85.5 |    25   |    1.4 |      4.2 |

*   **CAGR (Compound Annual Growth Rate):** Shows strong growth rates across all periods, with the most recent period (2023-2025) showing a significantly lower CAGR than previous periods.
*   **MDD (Maximum Drawdown):** MDD stays very high and almost consistent throughout all the periods, indicating significant price volatility and risk.
*   **Alpha:** Consistently high, demonstrating that TMDX's performance is driven more by factors specific to the company than by overall market movements, except the recent 2023-2025 period.
*   **Beta:** Fluctuates between 1.3 and 1.8, indicating that TMDX's price tends to move in the same direction as the market, but with more volatility.
*   **Cap(B) (Capitalization in Billions):** Showing the gradual increase in capitalization.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 121.65
*   **Last Market:** Price: 121.65, Previous Close: 121.92, Change: -0.22
*   **5-day SMA:** 123.56
*   **20-day SMA:** 128.32
*   **60-day SMA:** 126.18

**Analysis:** The stock price is currently below its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs), indicating a recent downward trend. The current price decrease is small.

**3. Technical Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 34.01
*   **PPO (Percentage Price Oscillator):** -0.75
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change (20 days):** -4.5 (Decreasing)
*   **Expected Return:** 208.76% (Over 2 years)

**Analysis:**

*   **MRI:** A high MRI suggests that, based on this indicator, the investment is considered to be very safe.
*   **RSI:** An RSI of 34.01 suggests the stock is nearing oversold territory, implying a potential for a rebound.
*   **PPO:** A negative PPO suggests a short-term downward trend.
*   **Hybrid Signal:** The signal recommends aggressive buying and investment.
*   **Divergence Change:** Recent decrease in relative divergence indicates a short-term decline in relative performance against the S&P 500.
*   **Expected Return:** The high expected return suggests strong potential for growth over the long term.

**4. Recent News & Significant Events (Yahoo Finance)**

*   Several articles highlight TransMedics as a strong growth stock and a potential buy. Analyst ratings have been upgraded.
*   One article mentions recent insider sales, which can sometimes be a cause for concern, but it is important to investigate the reasons for these sales.
*   Recent new hires receive stock options, which is a common practice and signals company growth and investment in its workforce.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.67)
*   **Opinions:** 11 analysts
*   **Target Price:** Average: $144.73, High: $170.00, Low: $114.00
*   **Recent Rating Changes:** No specific changes provided (empty parentheses).

**Analysis:** The overall analyst sentiment is positive, with a consensus "Buy" rating and a target price significantly above the current trading price. This suggests that analysts believe the stock is undervalued and has potential for further growth.

**5. Comprehensive Analysis**

TransMedics Group Inc. (TMDX) is a medical technology company with a focus on organ preservation. It has significantly outperformed the S&P 500 in recent years. While the stock has experienced some recent price weakness and is below its short-term moving averages, several factors suggest potential for future growth:

*   **Strong Fundamentals:** The company has demonstrated high growth rates and a strong alpha, indicating that its performance is driven by company-specific factors.
*   **Positive Analyst Sentiment:** Analysts have a consensus "Buy" rating with a target price significantly above the current price. Recent news articles also support the stock as a growth opportunity.
*   **High Expected Return:** The expected return is high.
*   **Technicals:** RSI near oversold territory could signal a potential rebound. The high MRI of 0.9 indicates that, based on this indicator, the investment is considered to be very safe.

**Concerns:**

*   **High MDD:** High MDD figures indicate significant price volatility and risk.
*   **Insider Sales:** The article referencing insider sales should be investigated further to understand the context and potential implications.

**Overall:**

TMDX presents a compelling growth opportunity, supported by strong fundamentals, positive analyst sentiment, and a high expected return. However, investors should be aware of the stock's volatility and the potential impact of insider sales. The recent stock price decline could represent a buying opportunity for long-term investors who believe in the company's growth potential. Due diligence is crucial before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.